US EditionLupin Achieves S&P Global ESG Score of 91 for 2025, Outpacing Pharmaceutical Industry Average
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Lupin achieves S&P Global ESG Score of 91 for 2025, outpacing pharmaceutical industry average
Lupin Limited (Lupin) announces that it has achieved an S & P Global ESG Score of 91 for 2025, well above the pharmaceutical industry average of 28. Lupin is now part of an exclusive group of companies worldwide that have surpassed the 90-point mark. This increase from 17 in 2021 ranks among the fastest for […] The post Lupin achieves S&P Global ESG Score of 91 for 2025, outpacing pharmaceutical industry average appeared first on MediaBrief.
Express Pharma
businessnewsweek.inLupin achieves S&P Global ESG Score of 91 for 2025, surpassing pharma industry average
Global pharma leader Lupin today announced that it has achieved an S&P Global ESG Score of 91 for 2025, well above the pharmaceutical industry average of 28. Lupin is now part of an exclusive group of companies worldwide that have surpassed the 90-point mark.* This increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth. Ramesh Swaminathan, Executive Director, Global CFO…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
